BM

Bltpur Madan Reddy

Active Director Director DIN 08711041
DIN 08711041 First appointment Feb 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2020
Shareholding value •••• Premium profile

About Bltpur Madan Reddy

Data last updated:

Bltpur Madan Reddy is a Director at Medicode Pharmaceuticals Private Limited (since 2020). The company operates in Pharma. Medicode Pharmaceuticals Private Limited reported revenue of ₹8,619 (FY 2021).

DIN 08711041
Primary Designation Director
Industry Pharma
First Appointment 26 Feb 2020
Oldest Company Age 6 yrs
Largest company Medicode Pharmaceuticals Private Limited · ₹8,619 (FY 2021)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director26 Feb 20202020₹8,619 (FY 2021)Active

Board colleagues of Bltpur Madan Reddy

Directorship timeline

Open interactive timeline →
Medicode Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Bltpur Madan Reddy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bltpur Madan Reddy

Bltpur Madan Reddy currently holds 1 directorship: Medicode Pharmaceuticals Private Limited (Director, since 26 Feb 2020, revenue ₹8,619 (FY 2021)).

Bltpur Madan Reddy was first appointed on 26 Feb 2020 as Director at Medicode Pharmaceuticals Private Limited.

The current boards of Bltpur Madan Reddy's companies include Bhaskar Reddy Nandepalli (Medicode Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available